Related Experiment Video

Updated: Jul 5, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy

Soonmo Peter Kang, Muhammad Wasif Saif

    JOP : Journal of the Pancreas
    |May 13, 2008
    PubMed

    Insights

    Pancreatic cancer is a genetic disease. Understanding its genetic alterations is key to overcoming drug resistance and developing new treatments for this common cancer.

    Area of Science:

    • Oncology
    • Genetics
    • Pharmacogenomics

    Background:

    • Pancreatic cancer affects over 30,000 Americans annually, with limited treatment advancements.
    • The disease is characterized by genetic alterations, highlighting its genetic basis.
    • Current therapeutic strategies for pancreatic cancer face significant challenges, including incremental progress.

    Discussion:

    • Pharmacogenomics offers a pathway to personalize pancreatic cancer treatment by understanding genetic variations.
    • Identifying specific carcinogenic gene alterations is crucial for overcoming therapeutic resistance.
    • This review explores the current landscape of pharmacogenomics in pancreatic cancer therapy.

    Key Insights:

    • Genetic alterations are fundamental to pancreatic cancer development and progression.
    • Understanding these alterations is essential for developing effective treatment strategies.
    • Pharmacogenomic approaches hold promise for improving patient outcomes.

    Outlook:

    • Future research should focus on elucidating the complex genetic landscape of pancreatic cancer.
    • Developing novel treatment approaches based on pharmacogenomic insights is a critical next step.
    • Personalized medicine strategies informed by genetic profiling will likely shape future pancreatic cancer care.

    More Related Videos

    Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies07:29

    Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

    Published on: June 20, 2015

    Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models09:18

    Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

    Published on: February 3, 2026

    Related Concept Videos

    Pharmacogenomics: Identification of New Drug Targets01:29

    Pharmacogenomics: Identification of New Drug Targets

    Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
    Pharmacogenetics and Pharmacogenomics: Overview01:29

    Pharmacogenetics and Pharmacogenomics: Overview

    Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

    Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...